65,437 trials
Diabetes Mellitus, Type 2
Primary: Change From Baseline in Glycosylated Hemoglobin (HbA1c) at 12 Weeks — -1.35; -1.15; -0.90; -0.18 percentage glycosylated hemoglobin — p=<.001
Mild to Moderate Hypertension
Primary: Area Under the Plasma Concentration-time Curve From Time Zero to the End of the Dosing Interval (AUCtau) of LCZ696 Analytes — 3700; 147000; 23600 h*ng/mL
Pain · Anesthesia
Primary: Mechanical Hyperalgesia Threshold on the Dominant Inner Forearm — 60.57; 78.29; 68.50; 79.7 g
Prolonged QT Interval in EKG and Sudden Death
Primary: Baseline (Pre-Ibutilide) QTcI Intervals — 412; 419 ms — p=0.04
Polycystic Ovary Syndrome
Primary: Estradiol During Phase I and Phase II — 451.7; 116; 247.2; 131.4 pmol/L
Healthy Japanese Children Age 2 Years Through 6 Years
Primary: Number of Participants With Solicited Symptoms Experienced From Administration of MEDI3250 — 57 subjects
Burns
Primary: Percentage of Patients With Earlier Healing of the Wound Half Treated With Oleogel-S10 Compared to the Wound Half Receiving Standard of Care — 85.7 percentage of…
Systemic Sclerosis
Primary: Percentage of Participants With Treatment-Emergent Adverse Events (AEs) — 96.9; 96.8 percentage of participants
Parastomal Hernia
Primary: Occurrence of Parastomal Hernia in Subjects Undergoing Permanent Abdominal Wall Ostomy Creation With and Without Strattice Fascial Inlay. — 6; 7 participants
Pressure Ulcers
Primary: Indicence of Pressure Ulcers — 0; 4 participants
Stage II Gallbladder Cancer · Stage IIIA Gallbladder Cancer · Stage IIIB Gallbladder Cancer
Primary: Response Rate According to RECIST Criteria — 3; 0 participants
Post-Traumatic Stress Disorder · Depression · Anxiety
Primary: Score Difference in Symptoms of Anxiety, Depression and Post-traumatic Stress Disorders. — -0.79; -0.42; -0.18; -0.48 units on a scale
Lymphoma · Hodgkin's Disease
Primary: Disease-free Survival — 76; 88; 70 percentage of participant
Alzheimer's Disease
Primary: Agreement Between Expert Panel and Clinical Practice Reads — 0.745 Weighted Kappa statistic
Hypophosphatasia · Bone Disease
Primary: Modified Performance-Oriented Mobility Assessment-Gait Subtest (MPOMA-G) - Change From Baseline to Last Overall — 1.50 units on a scale — p=0.0625